Why is aspirin listed as a risk factor in the TIMI NSTEMI score?

Aspirin use in the past 7 days counts as 1 risk point in TIMI NSTEMI because it paradoxically identifies higher-risk patients. Aspirin users in this context have previously recognized cardiovascular disease or risk factors (hence they were started on aspirin). Patients who develop ACS while on aspirin may have aspirin resistance or a higher underlying atherosclerotic burden — both associated with worse outcomes. The variable identifies sicker patients, not aspirin harm.

What antiplatelet therapy is recommended for NSTEMI?

ACC/AHA and ESC guidelines recommend dual antiplatelet therapy for NSTEMI: aspirin (81 mg, lifelong) plus a P2Y12 inhibitor. Preferred P2Y12 inhibitors: ticagrelor (90 mg twice daily, 12 months — PLATO trial showed 16% relative risk reduction vs. clopidogrel) or prasugrel (10 mg daily — preferred if going to PCI, from TRITON-TIMI 38). Clopidogrel is an acceptable alternative if ticagrelor/prasugrel are contraindicated. P2Y12 therapy continues for 12 months post-stent, with possible extension or shortening based on bleeding/ischemic risk.

What is high-sensitivity troponin and how does it change NSTEMI evaluation?

High-sensitivity troponin (hsTn) assays detect myocardial injury at much lower concentrations than conventional troponin assays. ESC 2020 guidelines recommend 0h/1h or 0h/2h hsTn protocols for rapid NSTEMI rule-in/rule-out. If hsTn is below the LoD at 0h and 1h with no clinical high-risk features, early discharge may be safe. Very high hsTn (>5x URL) at 0h strongly predicts type 1 MI. Serial hsTn rise >20% from 0h to 1-2h confirms NSTEMI. The TIMI biomarker criterion is satisfied by any hsTn above the 99th percentile upper reference limit.

What does ST deviation mean in the TIMI NSTEMI score?

ST deviation in TIMI NSTEMI includes ST depression ≥0.5 mm or transient ST elevation ≥0.5 mm in ≥2 contiguous leads on the presenting ECG. ST depression indicates subendocardial ischemia and correlates with worse prognosis in NSTEMI. New ST depression ≥1 mm is a particularly high-risk finding. ST changes in multiple lead territories suggest left main or proximal LAD disease. The TIMI ST deviation criterion requires only ≥0.5 mm, which is relatively sensitive.

Can the TIMI NSTEMI score be used for all chest pain patients?

TIMI NSTEMI was developed and validated specifically for patients with suspected or confirmed NSTEMI/unstable angina — it requires elevated cardiac biomarkers or typical ischemic symptoms with specific risk factors. For undifferentiated chest pain in the ED, the HEART score (History, ECG, Age, Risk Factors, Troponin) is better validated for broader chest pain risk stratification including non-ACS etiologies. TIMI NSTEMI is most accurate when applied to its intended population.

What are the 7 components of the TIMI NSTEMI score?

The 7 binary variables (1 point each): (1) Age ≥65 years; (2) ≥3 traditional CAD risk factors (family history of CAD, hypertension, hypercholesterolemia, diabetes, or active smoking); (3) Prior coronary stenosis ≥50% (known CAD, prior MI, or prior revascularization); (4) ST deviation ≥0.5 mm on presenting ECG; (5) ≥2 anginal events in the prior 24 hours; (6) Aspirin use in the past 7 days; (7) Elevated cardiac biomarkers (troponin or CK-MB above the 99th percentile upper reference limit). Total score range: 0-7.

What complications can occur after NSTEMI?

NSTEMI complications include: recurrent MI (most common, especially with incomplete revascularization), stent thrombosis (rare but catastrophic if P2Y12 discontinued prematurely), heart failure with reduced EF (if large myocardial territory infarcted), pericarditis, bleeding from antiplatelet/anticoagulant therapy, contrast nephropathy from catheterization, and vascular access complications (femoral vs. radial access — radial preferred to reduce bleeding). Post-NSTEMI LVEF should be assessed with echocardiography to determine need for GDMT and possible ICD evaluation.

Online Medical Tools — TIMI NSTEMI

Printed on 8/14/2026

For informational purposes only. This is not medical advice.

Cardiology

TIMI NSTEMI

The TIMI risk score for NSTEMI/UA uses 7 variables to stratify patients with non-ST elevation ACS. Scores range 0–7 and predict the 14-day risk of death, MI, or need for urgent revascularization, guiding decisions about invasive versus conservative management strategy.

Formula: Each criterion = 1 point. Age ≥65, CAD ≥50%, ASA use 7d, ≥2 angina 24h, ST dev ≥0.5mm, elevated biomarkers, ≥3 RF. Total 0–7.

Age ≥ 65 years

Known CAD (stenosis ≥ 50%)

Aspirin Use in Past 7 Days

≥ 2 Anginal Events in 24h

ST Deviation ≥ 0.5mm

Elevated Cardiac Biomarkers

≥ 3 CAD Risk Factors

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Score 7 clinical variables at NSTEMI/UA presentation

At the time of suspected NSTEMI or unstable angina presentation, score seven binary items (1 point each): age ≥65 years, ≥3 CAD risk factors (family history of CAD, hypertension, hypercholesterolemia, diabetes, or active smoking), prior coronary stenosis ≥50% (known CAD), ST deviation ≥0.5 mm on presenting ECG, ≥2 anginal events in the prior 24 hours, aspirin use in the past 7 days, and elevated cardiac biomarkers (troponin or CK-MB above the upper limit of normal).

Sum the points (0-7) and stratify risk

Sum all positive items to get a total score of 0-7. Stratification: low risk (0-2 points): 14-day MACE rate ~5-8%; moderate risk (3-4 points): ~13-20%; high risk (5-7 points): ~26-41%. The presence of elevated troponin and ST deviation are particularly important individual markers of myocardial injury and ongoing ischemia.

Guide early invasive vs. conservative management strategy

TIMI score ≥3 favors early invasive strategy — coronary angiography within 24-72 hours per ACC/AHA guidelines. Score 0-2 may support initial conservative management with medical therapy, serial troponins, and non-invasive stress testing. Note that the GRACE score is now the preferred tool per ACC/AHA 2014 guidelines for ACS risk stratification due to superior discrimination (C-statistic 0.77 vs. 0.65).

Who Uses the TIMI NSTEMI

NSTEMI/UA Risk Stratification in the ED

Emergency physicians, cardiologists

The TIMI NSTEMI score provides rapid, bedside risk stratification for patients presenting with suspected NSTEMI or unstable angina. It integrates readily available clinical data to estimate 14-day risk of major adverse cardiac events (MACE: death, MI, or urgent revascularization).

Guiding Early Invasive vs. Conservative Management

Interventional cardiologists, hospitalists

TIMI NSTEMI ≥3 is associated with a 14-day MACE rate ≥13%, favoring early invasive strategy with catheterization within 24-72 hours. Scores 0-2 (5-8% MACE rate) may support conservative initial management with medical therapy and staged risk assessment.

Catheterization Timing Prioritization

Cardiologists, interventionalists

High TIMI NSTEMI scores combined with high-sensitivity troponin elevation, ST changes, or hemodynamic instability identify patients who need emergent or urgent catheterization (<2 hours or <24 hours) rather than the standard early invasive approach within 24-72 hours.

Patient and Family Prognosis Communication

All clinicians managing ACS

A TIMI score of 6-7 (26-41% 14-day MACE) provides a concrete probability estimate for prognosis discussions with patients and families, helping to contextualize the urgency of invasive evaluation and the importance of dual antiplatelet therapy compliance.

ED Disposition Decisions

Emergency physicians, hospitalists

TIMI score contributes to emergency department disposition in chest pain presentations — whether the patient requires ICU monitoring, telemetry admission, or observation unit placement before stress testing. Higher scores support higher-level monitoring and earlier cardiology consultation.

Pro Tips

GRACE score is now preferred over TIMI NSTEMI per guidelines

The ACC/AHA 2014 NSTEMI Guidelines (Amsterdam et al., JACC 2014) and ESC 2020 NSTEMI Guidelines (Collet et al., Eur Heart J 2021) both recommend the GRACE score over TIMI NSTEMI for ACS risk stratification. GRACE achieves C-statistic 0.77 vs. TIMI NSTEMI at 0.65. Despite this, TIMI NSTEMI remains widely used clinically due to its simplicity and 7-item binary scoring system that can be calculated in seconds at the bedside.

Aspirin in past 7 days is a RISK FACTOR — not a protective factor

One of the most counterintuitive features of the TIMI NSTEMI score: aspirin use in the past 7 days adds 1 point (increases risk). This is not because aspirin causes harm — it is because aspirin use in the prior 7 days is a marker of previously recognized cardiovascular disease or aspirin resistance. A patient already on aspirin who develops ACS despite it has a higher baseline cardiovascular risk.

High-sensitivity troponin has largely replaced standard troponin

The TIMI NSTEMI score was developed with standard cardiac troponin. Modern practice uses high-sensitivity troponin (hsTn) with 0h/1h or 0h/2h protocols for rapid rule-in/rule-out. A single hsTn value at presentation above the upper limit of normal (99th percentile) satisfies the elevated biomarker criterion. Very low hsTn at 0h and 3h with no other high-risk features supports early discharge in the HEART Pathway and ESC guidelines.

Elevated troponin + ST deviation = emergent cath (<2 hours)

The combination of elevated troponin and new ST deviation is a very high-risk finding in NSTEMI. ACC/AHA and ESC guidelines recommend immediate invasive strategy (<2 hours) for NSTEMI patients with refractory ischemia, hemodynamic instability, sustained VT/VF, or signs of cardiogenic shock — regardless of TIMI score.

Ticagrelor or prasugrel preferred over clopidogrel for NSTEMI

ACC/AHA and ESC guidelines recommend ticagrelor (PLATO trial, 16% relative risk reduction vs. clopidogrel) or prasugrel (TRITON-TIMI 38, 19% relative risk reduction) for P2Y12 inhibition in NSTEMI over clopidogrel. Prasugrel is contraindicated in prior stroke/TIA and used with caution in age >75 and weight <60 kg. Ticagrelor is preferred for most NSTEMI patients.

Anticoagulation is required in all NSTEMI patients

All NSTEMI/UA patients should receive anticoagulation in addition to antiplatelet therapy. Options: unfractionated heparin (UFH), enoxaparin (preferred for medical management), bivalirudin (particularly for PCI), or fondaparinux (lowest bleeding risk for conservative strategy). Anticoagulation duration: until PCI, for 48 hours, or for the duration of hospitalization depending on strategy.

TIMI score does not capture renal function — a critical NSTEMI prognosticator

Unlike the GRACE score, TIMI NSTEMI does not include creatinine or estimated GFR. CKD is an independent predictor of NSTEMI mortality and affects drug dosing (enoxaparin, bivalirudin, contrast nephropathy risk). Always assess renal function separately in NSTEMI patients, especially when choosing anticoagulation and contrast-based procedures.

Two-hour high-sensitivity troponin protocols enable rapid risk stratification

ESC 2020 guidelines endorse 0h/2h hsTn protocols for rapid NSTEMI rule-in/rule-out. If hsTn is undetectable at 0h and negative at 2h with low clinical probability (HEART score ≤3, TIMI score 0), patients may be candidates for early discharge with outpatient follow-up. High-risk NSTEMI (hsTn rising, ST changes, TIMI ≥3) requires hospitalization and invasive evaluation.

Beta-blockers reduce ischemia in NSTEMI but avoid in acute decompensated HF

Oral beta-blockers should be started within 24 hours of NSTEMI for all patients without contraindications (acute decompensated HF, cardiogenic shock, significant bradycardia, or high-degree AV block). Intravenous beta-blockers are reserved for patients with refractory hypertension or tachycardia in the absence of LV dysfunction.

Common Questions About Your Results

No. These are completely different scoring systems. TIMI NSTEMI/UA (Antman et al., JAMA 2000) uses 7 binary variables to predict 14-day MACE in non-ST elevation ACS. TIMI STEMI (Morrow et al., Circulation 2000) uses 9 variables including age, hemodynamic parameters, and Killip class to predict 30-day mortality in ST-elevation MI. Using the wrong TIMI score for the wrong ACS presentation produces clinically meaningless results.

Aspirin use in the past 7 days is counterintuitively a risk factor in TIMI NSTEMI because it is a proxy marker for previously established cardiovascular disease or recognized high-risk status. A patient who presents with ACS despite being on aspirin therapy has either aspirin resistance or a higher baseline cardiovascular burden — both associated with worse prognosis. The variable identifies a sicker population, not aspirin toxicity.

GRACE is preferred by ACC/AHA 2014 and ESC 2020 guidelines as the primary ACS risk stratification tool because it has better discriminatory ability (C-statistic 0.77 vs. TIMI 0.65) and uses continuous variables (actual age, HR, BP, creatinine). GRACE should be used when a calculator is available and time permits. TIMI NSTEMI is useful for rapid bedside estimates in time-critical situations where GRACE cannot be quickly calculated.

A TIMI score of 0-2 indicates lower risk (5-8% 14-day MACE), but does not independently indicate safe ED discharge. Safe early discharge requires low TIMI score PLUS: no high-sensitivity troponin elevation on serial measurements, normal or near-normal ECG, no recurrent chest pain, no hemodynamic instability, and low-to-intermediate clinical pre-test probability. The HEART score or ESC 0h/2h hsTn pathway are more validated for early discharge decision-making than TIMI alone.

The five traditional CAD risk factors for TIMI NSTEMI scoring are: family history of premature CAD (first-degree relative with CAD at age <65 in females or <55 in males), hypertension (diagnosed or treated), hypercholesterolemia (diagnosed or on treatment), diabetes mellitus (diagnosed), and active cigarette smoking (current smoker). Having ≥3 of these 5 factors counts as 1 point. Note: age and sex are not counted as CAD risk factors in this criterion — they are separate variables.

Evidence-Based Methodology

TIMI Risk Score for UA/NSTEMI developed by Antman et al. (JAMA 2000) from 1,957 patients in TIMI 11B and validated in ESSENCE trial. C-statistic 0.65 for 14-day MACE. GRACE score (Eagle et al., Eur Heart J 2004) — C-statistic 0.77 — recommended as preferred tool in ACC/AHA 2014 NSTEMI Guidelines (Amsterdam et al., JACC 2014) and ESC 2020 NSTEMI Guidelines (Collet et al., Eur Heart J 2021). PLATO trial (Wallentin et al., NEJM 2009): ticagrelor superiority over clopidogrel. TRITON-TIMI 38 (Wiviott et al., NEJM 2007): prasugrel superiority over clopidogrel. ESC 0h/2h hsTn protocol validation: Shah et al. (Eur Heart J 2015).

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Your TIMI NSTEMI/UA score predicts the 14-day risk of a composite endpoint: all-cause death, new or recurrent myocardial infarction, or severe recurrent ischemia requiring urgent revascularization. A score of 0-2 indicates low risk (approximately 5-8% event rate), where conservative management with medical therapy and non-invasive stress testing may be appropriate. A score of 3-4 represents moderate risk (13-20%), and a score of 5-7 indicates high risk (26-41%), both of which favor an early invasive strategy with coronary angiography within 24-72 hours.

Each point in the TIMI NSTEMI score carries equal weight, making it simple to calculate at the bedside. However, the presence of elevated cardiac biomarkers (troponin) and ST deviation are particularly strong markers of ongoing ischemia and myocardial necrosis, and their presence should heighten clinical concern regardless of the total score.

When to Use This Tool

Use this score when evaluating patients presenting to the emergency department or chest pain unit with suspected non-ST elevation acute coronary syndrome (NSTEMI or unstable angina). It should be calculated after the initial ECG and troponin results are available. The score helps guide the critical decision of whether to pursue an early invasive strategy (catheterization within 24-72 hours) versus an initially conservative approach (medical management with possible later non-invasive testing).

The TIMI NSTEMI score is also useful for communicating risk to patients and families, for emergency department disposition decisions (admission to monitored bed vs. observation unit), and for identifying patients who may benefit from more aggressive antithrombotic therapy (glycoprotein IIb/IIIa inhibitors, early dual antiplatelet therapy).

Limitations

The TIMI NSTEMI score was derived from clinical trial populations (TIMI 11B and ESSENCE trials), which may not fully represent real-world emergency department patients. Trial exclusion criteria may have eliminated very high-risk and very low-risk patients, potentially affecting the score's calibration at the extremes.

The score uses binary variables, which limits its discriminative power compared to the GRACE score, which incorporates continuous variables such as age, heart rate, and creatinine. The TIMI score does not account for renal function, hemodynamic status, or heart failure, all of which are important prognostic factors in ACS. For these reasons, the ESC guidelines recommend the GRACE score as the preferred risk stratification tool, though the TIMI score remains widely used due to its simplicity and ease of bedside calculation.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Cardiology

TIMI STEMI

Calculate the TIMI risk score for STEMI to predict 30-day mortality.

Open Cardiology

GRACE Score

Calculate the GRACE score for in-hospital mortality risk in acute coronary syndrome patients.

Open Cardiology

HEART Score

Calculate the HEART Score to assess the risk of major adverse cardiac events (MACE) in patients presenting with chest pain.

Open

Frequently Asked Questions

The TIMI Risk Score for UA/NSTEMI is a 7-point bedside scoring tool developed by Antman et al. (JAMA 2000) to predict 14-day risk of major adverse cardiac events (death, new MI, or need for urgent revascularization) in patients presenting with non-ST elevation acute coronary syndrome. Each of the 7 binary variables contributes 1 point. Higher scores indicate greater 14-day MACE risk and favor earlier invasive management.

Early invasive strategy means coronary angiography with intent to revascularize within 24-72 hours of NSTEMI presentation. ACC/AHA guidelines recommend early invasive strategy for TIMI NSTEMI scores ≥3, elevated high-sensitivity troponin, new ST depression, signs of heart failure, hemodynamic instability, or GRACE score >140. Very high-risk features (hemodynamic instability, ongoing ischemia, cardiogenic shock, sustained VT) warrant immediate invasive strategy (<2 hours).

GRACE score is preferred by ACC/AHA 2014 and ESC 2020 NSTEMI guidelines over TIMI due to better discrimination (C-statistic 0.77 vs. 0.65 for TIMI). GRACE uses continuous variables (actual age, heart rate, blood pressure, creatinine) and includes Killip class and cardiac arrest at presentation, providing finer risk granularity. TIMI NSTEMI is easier to calculate mentally with 7 binary items and remains widely used for rapid bedside assessment.

NSTEMI treatment: (1) Antiplatelet therapy: aspirin + ticagrelor (preferred) or prasugrel or clopidogrel. (2) Anticoagulation: heparin, enoxaparin, bivalirudin, or fondaparinux. (3) Risk stratification using GRACE or TIMI score to determine timing of invasive evaluation. (4) Beta-blockers within 24 hours if no contraindications. (5) Statin therapy. (6) Coronary angiography: immediate (<2h) for very high-risk, early (<24h) for high-risk, within 24-72h for moderate-high TIMI/GRACE.

ACC/AHA and ESC guidelines recommend: Immediate invasive (<2 hours): hemodynamic instability, cardiogenic shock, refractory ischemia, sustained VT/VF, acute HF. Early invasive (<24 hours): GRACE >140, TIMI ≥3 with troponin rise or ST changes, post-cardiac arrest without ST elevation. Invasive within 24-72 hours: TIMI ≥3 without above high-risk features. Conservative (deferred, non-invasive): low GRACE/TIMI, absence of high-risk features, patient preference.

Online Medical Tools — TIMI NSTEMI

TIMI NSTEMI

How It Works

Score 7 clinical variables at NSTEMI/UA presentation

Sum the points (0-7) and stratify risk

Guide early invasive vs. conservative management strategy

Who Uses the TIMI NSTEMI

NSTEMI/UA Risk Stratification in the ED

Guiding Early Invasive vs. Conservative Management

Catheterization Timing Prioritization

Patient and Family Prognosis Communication

ED Disposition Decisions

Pro Tips

GRACE score is now preferred over TIMI NSTEMI per guidelines

Aspirin in past 7 days is a RISK FACTOR — not a protective factor

High-sensitivity troponin has largely replaced standard troponin

Elevated troponin + ST deviation = emergent cath (<2 hours)

Ticagrelor or prasugrel preferred over clopidogrel for NSTEMI

Anticoagulation is required in all NSTEMI patients

TIMI score does not capture renal function — a critical NSTEMI prognosticator

Two-hour high-sensitivity troponin protocols enable rapid risk stratification

Beta-blockers reduce ischemia in NSTEMI but avoid in acute decompensated HF

Common Questions About Your Results

Evidence-Based Methodology

Clinical Content Trust

How to Interpret Your Result

When to Use This Tool

Limitations

Changelog

Related Tools

TIMI STEMI

GRACE Score

HEART Score

Further Reading

A Complete Guide to Cardiology: Risk Scores, Heart Failure, and Cardiovascular Disease Management

Frequently Asked Questions